Cui Qianyu, Peng Yuming, Liu Xiaoyuan, Jia Bo, Dong Jia, Han Ruquan
Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
BMJ Open. 2017 Sep 11;7(9):e016521. doi: 10.1136/bmjopen-2017-016521.
Recent studies have shown that deep anaesthesia is associated with poor outcomes. However, no randomised controlled trials have been conducted to test the causality in patients undergoing brain tumour resection.
DEPTH is a multicenter, randomised, parallel-group, blind trial. The depth of general anaesthesia will be monitored using the bispectral index (BIS). Patients elected for supratentorial tumour resection will be randomly allocated to the deep or the light anaesthesia group in which the target BIS value is 35 or 50, respectively. BIS will be maintained at the target value for more than 90% of the total anaesthesia period. The primary outcome is the disability-free survival rate at postoperative 30 days and 1 year. The secondary outcomes are the mortality and morbidity within 30 days after surgery.
Ethical approval has been granted by the Medical Ethics Committee of Beijing Tiantan Hospital, Capital Medicine University. The reference number is KY2016-059-02. The results of this study will be disseminated through presentations at scientific conferences and publication in scientific journals.
NCT03033693.
近期研究表明,深度麻醉与不良预后相关。然而,尚未进行随机对照试验来检验脑肿瘤切除患者中的因果关系。
DEPTH是一项多中心、随机、平行组、盲法试验。将使用脑电双频指数(BIS)监测全身麻醉深度。择期进行幕上肿瘤切除的患者将被随机分配至深度麻醉组或浅麻醉组,其中目标BIS值分别为35或50。BIS将在总麻醉期的90%以上维持在目标值。主要结局是术后30天和1年时的无残疾生存率。次要结局是术后30天内的死亡率和发病率。
本研究已获得首都医科大学附属北京天坛医院医学伦理委员会的伦理批准。批准文号为KY2016 - 059 - 02。本研究结果将通过在科学会议上报告及在科学期刊上发表进行传播。
NCT03033693